Agrawal V, Singh A, Kaul A, Verma R, Jain M, Pandey R
Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Transplant Proc. 2017 Dec;49(10):2274-2279. doi: 10.1016/j.transproceed.2017.10.002.
With increasing graft survival, post-transplant immunoglobulin A nephropathy (IgAN) has emerged as an important cause of chronic graft dysfunction in renal allograft recipients. We studied the clinico-pathological features of post-transplant IgAN regardless of the primary disease. The aim was to study the usefulness of the Oxford classification in predicting survival.
Indication graft biopsy specimens (n = 915) were received during a 10-year period; 27 biopsy specimens from 22 patients were diagnosed as IgAN.
Post-transplant IgAN was seen in 2.6% of biopsy specimens. Mean time to occurrence was 71.6 ± 47.6 months (range, 6.8 months to 16 years), occurring most commonly 4 to 8 years after transplant. Associated rejection was present in 4 biopsies; 72.7% (16/22), 91% (20/22), and 31.8% (7/22) presented with rise in serum creatinine, proteinuria, and hematuria, respectively. Four (21%) patients had nephrotic range proteinuria. Mesangial hypercelullarity (M1), endocapillary hypercelullarity (E1), segmental glomerulosclerosis (S1), and tubulo-interstitial fibrosis (T1-2) was present in 36.6%, 22.7%, 54.5%, and 31.8% biopsies, respectively. The most frequent Haas class was III (n = 7; 29.1%), followed by classes IV and I (n = 5; 20.8% each). The 2- and 5-year graft survival rates were 75% and 56%, respectively. High serum creatinine, low estimated glomerular filtration rate, E1 and T lesions, and degree of interstitial inflammation predicted graft survival. Interestingly, percentage (>25%) of segmentally sclerosed glomeruli and not S1 correlated with graft outcome.
The Oxford MEST scheme is useful in predicting graft survival in post-transplant IgAN. The degree of interstitial inflammation is also an important feature for determining graft outcomes in post-transplant IgAN.
随着移植肾存活率的提高,移植后免疫球蛋白A肾病(IgAN)已成为肾移植受者慢性移植肾功能障碍的重要原因。我们研究了移植后IgAN的临床病理特征,而不考虑原发性疾病。目的是研究牛津分类法在预测存活率方面的实用性。
在10年期间共接收了指征性移植肾活检标本(n = 915);来自22例患者的27份活检标本被诊断为IgAN。
移植后IgAN在2.6%的活检标本中出现。发病的平均时间为71.6±47.6个月(范围为6.8个月至16年),最常见于移植后4至8年。4份活检标本存在相关排斥反应;分别有72.7%(16/22)、91%(20/22)和31.8%(7/22)的患者出现血清肌酐升高、蛋白尿和血尿。4例(21%)患者有肾病范围蛋白尿。系膜细胞增多(M1)、内皮细胞增多(E1)、节段性肾小球硬化(S1)和肾小管间质纤维化(T1-2)分别出现在36.6%、22.7%、54.5%和31.8%的活检标本中。最常见的Haas分级为Ⅲ级(n = 7;29.1%),其次是Ⅳ级和Ⅰ级(各n = 5;20.8%)。移植肾2年和5年存活率分别为75%和56%。高血清肌酐、低估计肾小球滤过率、E1和T病变以及间质炎症程度可预测移植肾存活。有趣的是,节段性硬化肾小球的百分比(>25%)而非S1与移植肾结局相关。
牛津MEST方案有助于预测移植后IgAN的移植肾存活。间质炎症程度也是决定移植后IgAN移植肾结局的重要特征。